Inqovi (decitabine-cedazuridine)

Numéro de dossier de l’AMC: 21608
État des négociations:
Négociation conclue avoir atteint une entente
Indication(s):
Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients
Promoteur/fabricant:
Taiho Pharma Canada Inc.
Numéro de projet de l’AMC:
PC0228-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation: